Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perspective TherapeuticsSTU:AAJ0 -0.24%35 Days Payable is 2,265.02 as of Jun. 2026, which is 4129% above its 10-year median of 53.56. GuruFocus rates STU:AAJ0 with a GF Score™ of 35/100 and a GF Value™ of €0.68 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Perspective Therapeutics ranks worse than 125470.39% on this metric.
The historical rank and industry rank for Perspective Therapeutics's Days Payable or its related term are showing as below:
During the past 13 years, Perspective Therapeutics's highest Days Payable was 90.38. The lowest was 43.66. And the median was 53.56.
STU:AAJ0's Days Payable is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 69.48 * Ranked among companies with meaningful Days Payable only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AAJ0 vs VMD, MOBI, RCEL: Days Payable Comparison
For the Medical Devices subindustry, Perspective Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perspective Therapeutics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Perspective Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Perspective Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics (STU:AAJ0) has a Days Payable of 2,265.02 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Perspective Therapeutics and its competitors. This is 4129% above median its historical median of 53.56. Over the past decade, Perspective Therapeutics' Days Payable has ranged from 43.66 to 90.38. According to the industry distribution chart, Perspective Therapeutics ranks #999999 out of 797 companies in the Medical Devices & Instruments industry.
Is Perspective Therapeutics' Days Payable too high?
Perspective Therapeutics' current Days Payable of 2,265.02 is 4129% above median its 10-year median of 53.56. Over the past 10 years, this metric has ranged from a low of 43.66 to a high of 90.38. The Medical Devices & Instruments industry median Days Payable is 69.48. Perspective Therapeutics' value of 2,265.02 is 3160% above this industry median. Based on the distribution chart, Perspective Therapeutics ranks #999999 out of 797 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Perspective Therapeutics has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Days Payable compare to VMD and MOBI?
According to the Medical Devices & Instruments industry distribution chart, Perspective Therapeutics ranks #999999 out of 797 companies for Days Payable. This places Perspective Therapeutics in the lower half of its industry. The industry median Days Payable is 69.48. Perspective Therapeutics' value of 2,265.02 is 3160% above this benchmark. Historically, Perspective Therapeutics' own Days Payable has ranged from 43.66 to 90.38 over the past decade. While the company's 10-year median is 53.56 vs. the industry median of 69.48, Perspective Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 69.48, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perspective Therapeutics's current Days Payable of 2,265.02 is 3160% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Perspective Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 69.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perspective Therapeutics's current Days Payable is 2,265.02, which is 4129% above median its own 10-year median of 53.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Perspective Therapeutics (STU:AAJ0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.68, compared to a current price of €2.48 — trading 264.1% above its estimated fair value. The current Days Payable is 2,265.02, which is 4129% above median its 10-year median of 53.56 and 3160% above the Medical Devices & Instruments industry median of 69.48. Perspective Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Perspective Therapeutics (STU:AAJ0), the current Days Payable is 2,265.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perspective Therapeutics (STU:AAJ0) Overvalued in 2026?
Based on GuruFocus' analysis, Perspective Therapeutics stock appears to be overvalued.
The current stock price of €2.48 is trading 264.1% above its estimated GF Value™ of €0.68.
GuruFocus considers Perspective Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:AAJ0:
Days Payable: 2,265.02 (4129% above median its 10-year median of 53.56)
GF Value™: €0.68 vs. price of €2.48 (264.1% above fair value)
Industry Position: 3160% above the Medical Devices & Instruments median (#999999 of 797)
No single metric tells the full story. See the STU:AAJ0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
35GF Score
Get the complete analysis for STU:AAJ0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AAJ0 has been successfully added to your 
